Kaposi Sarcoma Clinical Trials

14 recruiting

Kaposi Sarcoma Trials at a Glance

16 actively recruiting trials for kaposi sarcoma are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in Bethesda, St Louis, and New York. Lead sponsors running kaposi sarcoma studies include National Cancer Institute (NCI), AIDS Malignancy Consortium, and Washington University School of Medicine.

Browse kaposi sarcoma trials by phase

Treatments under study

About Kaposi Sarcoma Clinical Trials

Looking for clinical trials for Kaposi Sarcoma? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Kaposi Sarcoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Kaposi Sarcoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 116 of 16 trials

Recruiting
Phase 1Phase 2

Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma

Kaposi Sarcoma
National Cancer Institute (NCI)111 enrolled1 locationNCT04941274
Recruiting
Phase 1Phase 2

PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma

Kaposi Sarcoma
National Cancer Institute (NCI)80 enrolled1 locationNCT04303117
Recruiting
Phase 1

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

Kaposi SarcomaViral Associated MalignanciesEBV/KSHV-associated Lymphomas
National Cancer Institute (NCI)58 enrolled1 locationNCT04902443
Recruiting
Phase 2

Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)

KSHV Inflammatory Cytokine Syndrome (KICS)Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease
National Cancer Institute (NCI)75 enrolled1 locationNCT06052618
Recruiting

Natural History Study of Kaposi Sarcoma

Kaposi SarcomaHIV
National Cancer Institute (NCI)150 enrolled1 locationNCT06375122
Recruiting
Phase 2

Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)

Kaposi Sarcoma
National Cancer Institute (NCI)55 enrolled1 locationNCT07308886
Recruiting
Phase 2

Agnostic Therapy in Rare Solid Tumors

Cancer of Unknown PrimarySoft Tissue SarcomaCholangiocarcinoma+38 more
Instituto do Cancer do Estado de São Paulo28 enrolled8 locationsNCT06638931
Recruiting
Phase 2

Propranolol for the Treatment of Kaposi Sarcoma in Adults

Kaposi Sarcoma
Washington University School of Medicine25 enrolled1 locationNCT06445166
Recruiting

Precision Imaging to Evaluate Kaposi Sarcoma (PRIME-KS): A Device Feasibility Trial

Kaposi Sarcoma
Washington University School of Medicine30 enrolled1 locationNCT06751355
Recruiting
Phase 2

Trial of Ixazomib for Kaposi Sarcoma

Kaposi SarcomaSkin
AIDS Malignancy Consortium41 enrolled11 locationsNCT04305691
Recruiting
Not Applicable

AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW)

Cervical CancerKaposi Sarcoma
Implenomics4,100 enrolled1 locationNCT06004011
Recruiting
Phase 1

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

MelanomaHead and Neck Squamous Cell CarcinomaMetastatic Cancer+16 more
Memorial Sloan Kettering Cancer Center56 enrolled7 locationsNCT05859074
Recruiting

Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers

Anal CarcinomaMalignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+9 more
AIDS Malignancy Consortium200 enrolled8 locationsNCT05663502
Recruiting
Phase 1

Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi Sarcoma

Refractory HIV Associated Kaposi Sarcoma
Imperial College London20 enrolled1 locationNCT05646082
Recruiting

HHV8 and Solid Organ Transplantation

HHV8HHV8 InfectionHHV8-Related Malignant Neoplasm+5 more
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico250 enrolled1 locationNCT05081141
Recruiting
Phase 2

A Study of sEphB4-HSA in Kaposi Sarcoma

Kaposi Sarcoma
Vasgene Therapeutics, Inc65 enrolled3 locationsNCT03993106